BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 10773542)

  • 1. Assessment of the in vitro and in vivo properties of a (99m)Tc-labeled inhibitor of the multidrug resistant gene product P-glycoprotein.
    Bergmann R; Brust P; Scheunemann M; Pietzsch HJ; Seifert S; Roux F; Johannsen B
    Nucl Med Biol; 2000 Feb; 27(2):135-41. PubMed ID: 10773542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance.
    Márián T; Szabó G; Goda K; Nagy H; Szincsák N; Juhász I; Galuska L; Balkay L; Mikecz P; Trón L; Krasznai Z
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1147-54. PubMed ID: 12830325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line.
    Utsunomiya K; Ballinger JR; Piquette-Miller M; Rauth AM; Tang W; Su ZF; Ichise M
    Eur J Nucl Med; 2000 Dec; 27(12):1786-92. PubMed ID: 11189941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein.
    Crankshaw CL; Marmion M; Luker GD; Rao V; Dahlheimer J; Burleigh BD; Webb E; Deutsch KF; Piwnica-Worms D
    J Nucl Med; 1998 Jan; 39(1):77-86. PubMed ID: 9443741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin.
    Gomes CM; Abrunhosa AJ; Pauwels EK; Botelho MF
    Cancer Biother Radiopharm; 2009 Apr; 24(2):215-27. PubMed ID: 19409044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.
    Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D
    Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TC-99m MIBI SPECT imaging in patients with lung carcinoma: is it a functional probe of multidrug resistance genes?
    Ak I; Gülbaş Z; Ocak S; Kaya E; Alataş F; Vardareli E; Metintaş M
    J Comput Assist Tomogr; 2007; 31(5):795-9. PubMed ID: 17895794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET?
    Yokogami K; Kawano H; Moriyama T; Uehara H; Sameshima T; Oku T; Goya T; Wakisaka S; Nagamachi S; Jinnouchi S; Tamura S
    Eur J Nucl Med; 1998 Apr; 25(4):401-9. PubMed ID: 9553170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Technetium-99m sestamibi single photon emission computed tomography findings correlated with P-glycoprotein expression, encoded by the multidrug resistance gene-1 messenger ribonucleic acid, in intracranial meningiomas.
    Kunishio K; Morisaki K; Matsumoto Y; Nagao S; Nishiyama Y
    Neurol Med Chir (Tokyo); 2003 Dec; 43(12):573-80; discussion 581. PubMed ID: 14723263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells.
    Moretti JL; Duran Cordobes M; Starzec A; de Beco V; Vergote J; Benazzouz F; Boissier B; Cohen H; Safi N; Piperno-Neumann S; Kouyoumdjian JC
    J Nucl Med; 1998 Jul; 39(7):1214-8. PubMed ID: 9669397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visualization of multidrug resistance in vivo.
    Hendrikse NH; Franssen EJ; van der Graaf WT; Vaalburg W; de Vries EG
    Eur J Nucl Med; 1999 Mar; 26(3):283-93. PubMed ID: 10079321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of multidrug resistance protein and messenger RNA correlate with (99m)Tc-MIBI imaging in patients with lung cancer.
    Zhou J; Higashi K; Ueda Y; Kodama Y; Guo D; Jisaki F; Sakurai A; Takegami T; Katsuda S; Yamamoto I
    J Nucl Med; 2001 Oct; 42(10):1476-83. PubMed ID: 11585860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines.
    Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Peters AM
    Acta Oncol; 2004; 43(5):443-52. PubMed ID: 15360048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
    Agrawal M; Abraham J; Balis FM; Edgerly M; Stein WD; Bates S; Fojo T; Chen CC
    Clin Cancer Res; 2003 Feb; 9(2):650-6. PubMed ID: 12576431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.
    Luker GD; Rao VV; Crankshaw CL; Dahlheimer J; Piwnica-Worms D
    Biochemistry; 1997 Nov; 36(46):14218-27. PubMed ID: 9369495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation.
    Piwnica-Worms D; Rao VV; Kronauge JF; Croop JM
    Biochemistry; 1995 Sep; 34(38):12210-20. PubMed ID: 7547962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
    Kelly RJ; Robey RW; Chen CC; Draper D; Luchenko V; Barnett D; Oldham RK; Caluag Z; Frye AR; Steinberg SM; Fojo T; Bates SE
    Oncologist; 2012; 17(4):512. PubMed ID: 22416063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting multidrug resistance-related protein and P-glycoprotein expression with technetium-99m tetrofosmin mammoscintigraphy.
    Liu TJ; Shiau YC; Tsai SC; Wang JJ; Ho ST; Kao A
    Breast; 2003 Feb; 12(1):58-62. PubMed ID: 14659356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
    Rieger L; Rieger J; Winter S; Streffer J; Esser P; Dichgans J; Meyermann R; Weller M
    Acta Neuropathol; 2000 May; 99(5):555-62. PubMed ID: 10805101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of the glutathione S-conjugate compounds and the MRP protein in Tc-99m-tetrofosmin and Tc-99m-sestamibi uptake in glioma cell lines.
    Perek N; Prevot N; Koumanov F; Frere D; Sabido O; Beauchesne P; Dubois F
    Nucl Med Biol; 2000 Apr; 27(3):299-307. PubMed ID: 10832087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.